Galmed Pharmaceuticals Ltd. (GLMD) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 3.04M | 2.1M | 2.11M | 1.26M | 1.64M | 2.01M | 1.22M | 1.4M | 2.15M | 1.47M | 1.87M | 2M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 946K | 1.01M | 1.05M | 630K | 572K | 1.27M | 688K | 766K | 1.03M | 912K | 1.06M | 919K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.1M | 1.09M | 1.06M | 634K | 1.07M | 738K | 534K | 635K | 1.12M | 556K | 809K | 1.08M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.04M | -2.1M | -2.11M | -1.26M | -1.64M | -2.01M | -1.22M | -1.4M | -2.15M | -1.47M | -1.87M | -2M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -85.04% | -4.18% | -72.59% | 9.78% | 23.57% | -36.99% | 34.69% | 30.02% | 12.17% | 72.71% | 49.84% | 67.14% |
| EBITDA | -3.04M | -2.1M | -2.11M | -1.26M | -1.64M | -2.01M | -1.15M | -1.39M | -2.15M | -1.46M | -1.86M | -1.99M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -85.04% | -4.18% | -83.71% | 9.2% | 23.36% | -37.74% | 38.35% | 30.19% | 12.09% | 72.82% | 49.96% | 67.22% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 74K | 9K | 6K | 8K | 9K | 8K |
| EBIT | -3.04M | -2.1M | -2.11M | -1.26M | -1.64M | -2.01M | -1.22M | -1.4M | -2.15M | -1.47M | -1.87M | -2M |
| Net Interest Income | 411K | 203K | 140K | 160K | -448K | 97K | 103K | 126K | 135K | -5K | 278K | 172K |
| Interest Income | 411K | 203K | 140K | 160K | 0 | 97K | 103K | 126K | 135K | 0 | 278K | 172K |
| Interest Expense | 0 | 0 | 0 | 0 | 448K | 0 | 0 | 0 | 0 | 5K | 0 | 0 |
| Other Income/Expense | -1.78M | 203K | -386K | 160K | -1.56M | 97K | 103K | 126K | 135K | -5K | 278K | 172K |
| Pretax Income | -4.82M | -1.89M | -2.5M | -1.1M | -3.21M | -1.91M | -1.12M | -1.27M | -2.02M | -1.47M | -1.59M | -1.83M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.82M | -1.89M | -2.5M | -1.1M | -3.21M | -1.91M | -1.12M | -1.27M | -2.02M | -1.47M | -1.59M | -1.83M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -50.14% | 1.15% | -122.97% | 13.41% | -59.18% | -29.94% | 29.76% | 30.33% | 23.61% | 72.47% | 57.34% | 70.21% |
| Net Income (Continuing) | -4.82M | -1.89M | -2.5M | -1.1M | -3.21M | -1.91M | -1.12M | -1.27M | -2.02M | -1.47M | -1.59M | -1.83M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.73 | -0.35 | -0.63 | -0.62 | -46.42 | -27.69 | -2.13 | -0.23 | -0.40 | -0.24 | -0.95 | -0.99 |
| EPS Growth % | 98.43% | 98.74% | 70.42% | -169.57% | -11505% | -11437.5% | -124.21% | 76.77% | 76.19% | 92.5% | 57.4% | 73.24% |
| EPS (Basic) | -0.73 | -0.35 | -0.63 | -0.62 | -46.42 | -27.69 | -2.13 | -0.23 | -0.40 | -0.24 | -0.95 | -0.99 |
| Diluted Shares Outstanding | 6.58M | 5.46M | 3.95M | 1.78M | 1.61M | 69.13K | 524.56K | 5.46M | 5.05M | 6.25M | 1.68M | 1.68M |
| Basic Shares Outstanding | 6.58M | 5.46M | 3.95M | 1.78M | 1.61M | 69.13K | 524.56K | 5.46M | 5.05M | 6.25M | 1.68M | 1.68M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |